Editas Medicine: O'Neill plans 5,100-share sale

Editas Medicine, Inc. (EDIT) is the issuer for which Gilmore O'Neill filed a Form 144 notice to potentially sell common stock under Rule 144.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) is the issuer for which Gilmore O'Neill filed a Form 144 notice to potentially sell common stock under Rule 144. The notice covers a proposed sale of 5,100 shares of Editas Medicine common stock through E*Trade, with an aggregate market value of $16,728.00 and an anticipated sale date of September 3, 2026 on NASDAQ. The securities relate to 11,294 shares acquired from restricted stock unit vesting on September 2, 2026. The filing also reports that O'Neill sold 15,380 shares of Editas Medicine common stock for $41,542.92 on June 3, 2026 during the prior three months.

Key Figures

Shares proposed for sale: 5,100 shares of common stock Aggregate market value of proposed sale: $16,728.00 Shares acquired via Restricted Stock Unit Vesting: 11,294 shares +2 more

5 metrics

Shares proposed for sale 5,100 shares of common stock Proposed Rule 144 sale through E*Trade on September 3, 2026

Aggregate market value of proposed sale $16,728.00 Estimated value for 5,100 shares of Editas Medicine common stock

Shares acquired via Restricted Stock Unit Vesting 11,294 shares Equity compensation from issuer on September 2, 2026

Shares sold during past 3 months 15,380 shares Sale by Gilmore O'Neill on June 3, 2026

Proceeds from past 3-month sale $41,542.92 Total proceeds from 15,380 Editas Medicine shares sold June 3, 2026

Key Terms

Rule 144, Restricted Stock Unit Vesting, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Vesting financial

"Common Stock | 09/02/2026 | Restricted Stock Unit Vesting | Issuer"

Equity Compensation financial

"11294 | 09/02/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

What does the Form 144 filing for EDIT disclose about Gilmore O'Neill's planned sale?

The Form 144 indicates Gilmore O'Neill plans a potential sale of 5,100 shares of Editas Medicine (EDIT) common stock through E*Trade, with an aggregate market value of $16,728.00, expected to be sold on September 3, 2026 on NASDAQ under Rule 144.

How many Editas Medicine (EDIT) shares related to equity awards are referenced in this Form 144?

The filing states that 11,294 shares of Editas Medicine common stock were acquired on September 2, 2026 through Restricted Stock Unit Vesting as equity compensation from the issuer.

What prior Editas Medicine (EDIT) stock sales by Gilmore O'Neill are reported?

The Form 144 reports that Gilmore O'Neill sold 15,380 shares of Editas Medicine common stock on June 3, 2026 for total proceeds of $41,542.92 during the past three months.

Which broker and market are involved in the planned Editas Medicine (EDIT) share sale?

The filing lists E*Trade Corporation as the broker for the proposed sale of Editas Medicine common stock, with the shares expected to be sold on the NASDAQ market on or about September 3, 2026.

Who is the person filing the Form 144 related to Editas Medicine (EDIT)?

The Form 144 is filed for the account of Gilmore O'Neill, in connection with potential sales of Editas Medicine (EDIT) common stock under Rule 144 and securities acquired via restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:11 PM Accepted by SEC EDGAR 08/31/2026 - 04:11 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001742084
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Editas Medicine, Inc.
SEC File Number	001-37687
Address of Issuer	11 HURLEY ST. CAMBRIDGE MASSACHUSETTS 02141
Phone	617-401-9000
Name of Person for Whose Account the Securities are To Be Sold	O'Neill Gilmore Neil
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E Trade Corporation 3 Edison Financial Alphareta GA 30005	5100	16728.00	153580035	09/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/02/2026	Restricted Stock Unit Vesting	Issuer			11294	09/02/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Gilmore O'Neill 11 Hurley Street Cambridge MA 02141	Common Stock	06/03/2026	15380	41542.92

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/13/2022
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Gilmore O'Neill
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)